Tag:
Synthes
Latest Headlines
Latest Headlines
J&J's Gorsky looks to unload $2B diagnostics unit in biz reshuffle
A big development in the diagnostics industry emerged in Johnson & Johnson's heavy stream of earnings news today. The healthcare giant ($JNJ) is mulling options for its Ortho Clinical Diagnostics business, as CEO Alex Gorsky moves to emphasize the company's best prospects for growth.
J&J device revenue jumped 6.4% in 2012 thanks to Synthes buy
Johnson & Johnson paid a pretty penny for orthopedics giant Synthes, but last year's $21.3 billion acquisition made quite a mark on the company's annual report, as J&J posted 6.4% revenue growth in its devices division and a 34.3% jump in its ortho business.
J&J medical device sales soar on Synthes buy
Johnson & Johnson's $21.3 billion Synthes acquisition is starting to pay off, as the company reported a 12.5% third-quarter increase in medical device sales due largely to its fresh-bought orthopedics offerings.
Former Synthes execs blacklisted over bone cement scandal
Now that they've completed their stints in federal prison, four former Synthes executives have been essentially banished from the healthcare industry for their roles in the Norian bone cement scandal that left three dead.
J&J's Synthes recalls bone putty over fire risk
Johnson & Johnson's Synthes unit launched a recall of its Hemostatic Bone Putty, warning that the implant could catch fire if exposed to cautery systems during surgery, and the FDA has slapped its most serious label on the affair.
Biomet closing $280M bid for DePuy's global trauma biz
Biomet has begun a gradual process to complete its $280 million cash bid of the global trauma business of DePuy Orthopaedics, a Johnson & Johnson-owned ($JNJ) company.
J&J's $21.3B bid for orthopedic devicemaker Synthes nearly done
Johnson & Johnson's ($JNJ) $21.3 billion bid to buy Swiss orthopedic device maker Synthes is finally reaching the regulatory finish line.
J&J gains EU nod for $21.3B Synthes deal
It took a year after the initial announcement, but Johnson & Johnson ($JNJ) finally gained European regulatory approval for its $21.3 billion bid to buy Synthes.
Ex-Synthes employee fights back in generic device tussle
Synthes is fighting an ex-employee in court alleging, among other things, illegal use of proprietary information. This week, he's fighting back.
FDA threatens fines, regulatory action over Synthes' GMP problems
Synthes has been producing rods, power tools and screws for orthopedics for years. But now the FDA is putting the screws to Synthes.
